Format

Send to

Choose Destination
Bioimpacts. 2019;9(1):1-3. doi: 10.15171/bi.2019.01. Epub 2018 Oct 21.

Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities.

Author information

1
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
2
Students' Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
3
Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract

Trafficking of macromolecular immunotherapy agent into the tumor microenvironment (TME) is a challenging issue. In the TME, cancer cells exploit indoleamine 2, 3-dioxygenase (IDO), as a cytosolic enzyme that catalyzes the L-tryptophan (Trp) through the kynurenine (Kyn) pathway, which could negatively regulate the activity of T cells. Thus, Trp/Kyn pathway, can be targeted with novel treatment modalities such as IDO1 inhibitor to benefit patients with aggressive solid tumors.

KEYWORDS:

Cancer therapy; IDO inhibitor; Immunotherapy; Indoleamine 2, 3-dioxygenase; Kynurenine; Solid tumors

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center